Policy & Regulation
Neuraptive Therapeutics Activates First Clinical Site in Phase 2 Study of NTX-001 for the Treatment of Nerve Repair
22 October 2020 - - US-based biotechnology company Neuraptive Therapeutics, Inc has activated the first clinical site of its Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Patients with Acute Single Transected Peripheral Nerve Injuries of the Upper Extremities, the company said.

Additionally, Neuraptive appointed David Pierce to the board of directors. Pierce is currently executive vice president and president of the MedSurg business at Boston Scientific.

He brings more than 25 years of commercial and strategic medical technology experience to the board.

Pierce is currently executive vice president and president of the MedSurg business at Boston Scientific, a position he has held since April of 2018.

Pierce began his career with Boston scientific in 1991 as a territory manager and has held roles of increasing responsibility.

While at Boston Scientific, Pierce developed and executed strategies to bring to market industry-leading solutions across a range of medical areas.

Before Boston Scientific, Pierce served as a senior sales representative for Airborne Express and a Captain in the United States Army.

Neuraptive is creating innovative novel therapies for nerve repairs to improve clinical outcomes for patients and surgeons who care for them.

The company's franchise therapeutic product, NTX-001, has the potential to improve the quality and speed of recovery of nerve sensation and function for eligible patients who have sustained traumatic injuries or who are undergoing reconstructive surgical procedures and has received Fast Track Designation from the FDA.

Neuraptive is rapidly advancing its pipeline and will leverage its capabilities to transition into a clinical-stage company.

The company is headquartered in Philadelphia, PA.


Related Headlines